Please wait while the formulary information is being retrieved.
ZINECARD (DEXRAZOXANE HCL)
- Doxorubicin-induced cardiomyopathy
(as HCl) 250 mg intravenous solution
- Dosage information is not available
(as HCl) 500 mg intravenous solution
- Dosage information is not available
250 mg intravenous solution
- Dosage information is not available
500 mg intravenous solution
- Dosage information is not available
HCl 250 mg intravenous solution
- Dosage information is not available
HCl 500 mg intravenous solution
- Dosage information is not available
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Leukopenia
- Neutropenic disorder
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- Kidney disease with likely reduction in GFR
ZINECARD (DEXRAZOXANE HCL)
- Doxorubicin-induced cardiomyopathy
- None
- Diarrhea
- Fever
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Bacterial sepsis
- Hemorrhage
- Injection site sequelae
- Urticaria
- Erythema
- Peripheral neuropathy
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory distress syndrome
- Anaphylaxis
- Angioedema
- Bronchospastic pulmonary disease
- Hypotension
- Leukopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- Unconsciousness
Less Severe
- Skin rash
Contraindicated
None
Severe Precaution
Dexrazoxane
Not indicated in pediatrics. Reports of secondary malignancy reported when used with chemotherapy.
- 1 Day – 18 Years
- Not indicated in pediatrics. Reports of secondary malignancy reported when used with chemotherapy.
Management or Monitoring Precaution
None
Dexrazoxane
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Dexrazoxane
Breastfeeding not recommended due to potential risk to infant
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Breastfeeding not recommended due to potential risk to infant |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Doxorubicin-induced cardiomyopathy | |
| I42.7 | Cardiomyopathy due to drug and external agent |
| 0-9 | A-Z |
|---|---|
| I42.7 | Cardiomyopathy due to drug and external agent |
Formulary Reference Tool